Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-02
2007-01-02
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S139000
Reexamination Certificate
active
10181051
ABSTRACT:
The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I)processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
REFERENCES:
patent: 2811555 (1957-10-01), Larive et al.
patent: 3279880 (1966-10-01), Straley et al.
patent: 4500519 (1985-02-01), Lormeau et al.
patent: 4705779 (1987-11-01), Madi-Szabo et al.
patent: 5254577 (1993-10-01), Carlson et al.
patent: 5349045 (1994-09-01), Jiang
patent: 5532255 (1996-07-01), Raddatz et al.
patent: 5561148 (1996-10-01), Gante et al.
patent: 5565571 (1996-10-01), Barbachyn et al.
patent: 5654428 (1997-08-01), Barbachyn et al.
patent: 5654435 (1997-08-01), Barbachyn et al.
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 5756732 (1998-05-01), Barbachyn et al.
patent: 5792765 (1998-08-01), Riedl et al.
patent: 5801246 (1998-09-01), Barbachyn et al.
patent: 5827857 (1998-10-01), Riedl et al.
patent: 5910504 (1999-06-01), Hutchinson et al.
patent: 5922708 (1999-07-01), Riedl et al.
patent: 5929248 (1999-07-01), Barbachyn et al.
patent: 5972947 (1999-10-01), Tsaklakidis et al.
patent: 6069160 (2000-05-01), Stolle et al.
patent: 6251869 (2001-06-01), Bohanon
patent: 744002 (1999-07-01), None
patent: 2 437 587 (2002-08-01), None
patent: 2 451 258 (2003-01-01), None
patent: 2 464 290 (2003-05-01), None
patent: 196 04 223 (1997-08-01), None
patent: 0 127 902 (1984-12-01), None
patent: 0 316 594 (1989-05-01), None
patent: 0 352 781 (1990-01-01), None
patent: 0 623 615 (1994-11-01), None
patent: 0645376 (1995-03-01), None
patent: 0 738 726 (1996-10-01), None
patent: 0 785 200 (1997-07-01), None
patent: WO-93/09103 (1993-05-01), None
patent: WO-93/23384 (1993-11-01), None
patent: WO-97/03072 (1997-01-01), None
patent: WO-97/09328 (1997-03-01), None
patent: WO-97/10223 (1997-03-01), None
patent: WO-98/01446 (1998-01-01), None
patent: WO-98/54161 (1998-12-01), None
patent: WO-99/02525 (1999-01-01), None
patent: WO-99/03846 (1999-01-01), None
patent: 9906371 (1999-02-01), None
patent: WO-99/24428 (1999-05-01), None
patent: WO-99/29688 (1999-06-01), None
patent: WO-99-31092 (1999-06-01), None
patent: 9937304 (1999-07-01), None
patent: WO-99/37630 (1999-07-01), None
patent: WO-99/37641 (1999-07-01), None
patent: WO-99/40094 (1999-08-01), None
patent: WO-99/59616 (1999-11-01), None
patent: WO-01/42242 (2001-06-01), None
patent: WO-01/44212 (2001-06-01), None
patent: WO-01/46185 (2001-06-01), None
patent: WO-02/064575 (2002-08-01), None
patent: WO-03/000256 (2003-01-01), None
patent: WO-03/035133 (2003-05-01), None
*This reference is not being furnished since it was cited in the International Search Report for PCT/EP 00/12492.
Cancer and Metastasis Review, vol. 17, pp. 91-106, (1998).
Science (1999), vol. 286, 531-537.
FDA mulls drug to slow late-stage Alzheimers's [online], [retrieved on Sep. 9, 2003]. Retrieved from the internet, URL;http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
Ullmann's Encycolpedia of Industrial Chemistry, Fifth Revised Ed., Editors.: Elvers, B., Hawkins, S., VCH Verlagsgesellschaft mbH, Weinheim, 1985-1996, ch. 5, 488-506.
Zhu, B., Scarborough, R., “Recent Advances in Inhibitors of Factor Xa in the Prothrombinase Complex”, Cur. Opinions Card. Pulm. Ren. Inv. Drugs, 1: 63-87 (1999).
Uzan, A., “Antithrombotic Agents”, Emerging Drugs: The Prospect for Improved Medicines, 3: 189-208, (1998).
Kaiser, B., “Thrombin and Factor Xa Inhibitors”, Drugs of the Future, 23: 423-436 (1998).
Al-Obeidi, F., Ostrem, J., “Factor Xa Inhibitors”, Expert Opin. Therapeutic Patents, 9: 931-953 (1999).
Al-Obeidi, F., Ostrem, J., “Factor Xa Inhibitors by Classical and Combinatorial Chemistry”, DDT, 3: 223-231 (May 1998).
Hauptmann, J., Sturzebecher, J., “Synthetic Inhibitors of Thrombin and FActor Xa: From Bench to Bedside”, Thrombosis Research, 93: 203-241 (1999).
Pschyrembel, Klinisches Worterbuch, 257. Auflage, 1994, Walter de Gruyter Verlag, p. 199-200, Stichwort “Blutgerinnung”.
Rompp Lexikon Chemie, Ver. 1.5, 1998, Georg Thieme Verlag Stuttgart, Stichwort “Blutgerinnung” Lubert Stryer, Biochemie, Spektrum der Wissenschaft Verlagsgesellschaft mbH Heidelberg, 1990, p. 259.
Pschyrembel, Klinisches Worterbuch, 257. Auflage, 1994, Walter de Gruyter Verlag, p. 610, Stichwort “Heparin”.
Rompp Lexikon Chemie, Ver. 1.5, 1998, Georg Thieme Verlag Stuttgart, Stichwort “Heparin”.
Pschyrembel, Klinisches Worterbuch, 257. Auflage, 1994, Walter de Gruyter Verlag, p. 292, Stichwort “Cumarinderivate”.
Becker, M. R., Ewing, W. R., Davis, R. S., Pauls, H. W., Ly, C., Li, A., Mason, H. J., Choi-Sledeski, Y. M., Spada, A. P., Chu, V., Brown, K. D., Colussi, D. J., Leadley, R. J., Bentley, R., Bostwick, J., Kasiewski, C., and Morgan, S., “Synthesis, Sar and in Vivo Activity of Novel Thienopyridine Sulfonamide Pyrrolidinones as Factor Xa Inhibitors”, Bioorganic & Medicinal Chemistry Letters, 9: 2753-2758 (1999).
Adams et al., Sulfanilamide Derivatives, J. Am. Chem. Soc. 1939, vol. 61, pp. 2342-2349.
Aebischer et al., Synthesis of N-Arylrolipram Derivatives—Potent and Selective Phosphodiesterase-IV Inhibitors— By Copper Catalyzed Lactam-Aryl Halide Coupling, Hetercycles. 1998, vol. 48, pp. 2225-2229.
Artico et al., Research on Compounds with Antiblastic Activity, Farmaco Ed. Sci. 1969, vol. 24, pp. 179-190.
Barbachyn et al., Identification of a Novel Oxazolidinone ( U-100480) with Potent Antimycobacterial Activity, J. Med. Chem. 1996, vol. 39, pp. 680-685.
Bartoli et al., Electronic and Steric Effects in Nucleophilic Aromatic Substitution. Reaction by Phenoxides as Nucleophiles in Dimethyl Sulfoxide, J. Org. Chem. 1975, vol. 40, pp. 872-874.
Berry et al., Antithrombotic Actions of Argatroban in Rat Models of Venous, ‘Mixed’and Arterial Thrombosis, and its Effects on the Tail Transection Bleeding Time, Br. J. Pharmacol. 1994, vol. 113, pp. 1209-1214.
Bouchet et al., ∂Values of N-Substituted Azoles, J. Chem. Soc. Perkin Trans. 1974, vol. 2, pp. 449-451.
Brickner et al., Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone ANtibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections, J. Med. Chem. 1996, vol. 39, pp. 673.
Chern et al., Studies on Quinazolines IX: Fluorination versus 1,2-Migration in the Reaction of 1,3-Bifunctionalized amino-2-propanol with DAST, Tetrahedron Lett. 1998, vol. 39, pp. 8483-8486.
Dankwardt et al., Nonpeptide Bradykinin Antagonist Analogs Based on a Model of a Sterling-Winthrop Nonpeptide brandykinin Antagonist Overlapped with Cyclic Hexapeptide Bradykinin Antagonist Peptides, Bioorg. Med. Chem. Lett. 1997, vol. 7, No. 14, pp. 1921-1926.
Dostert et al., 5-Hydroxymethyl-2-oxazolidinones, Chem. Abstr. 1979, vol. 90, pp. 186926.
Gregory et al., Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The “B” Group, J. Med. Chem. 1989, vol. 32, pp. 1673-1681.
Grell et al., Repaglinide and Related Hypoglycemic Benzoic Acid Derivatives, J. Med. Chem. 1998, vol. 41, pp. 5219-5246.
Gutcait et al., Studies on Quinazolines. 6. Asymmetric Synthesis of (S)-(30 )-and (R)-(-)-3-[[4-(2-Methoxyphenyl)piperazin-1yl]methyl]-5-methylthio-2,3-dihydroimidazo[1,2-c]quinazolines, Tetrahedron Asym. 1996, vol. 7, pp. 1641-1648.
Khanna et al., 1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2, J. Med. Chem. 1997, vol. 40, pp. 1619-1633.
Luvalle et al., Oxidation Processes. XXI. The Autoxidation of the p-Phenylenediamines, J. Am. Chem. Soc. 1948, vol. 70, pp. 2223-2233.
Meng et al., Effect of Acetylsalicylic Acid on Experimentally Induced Arterial Thrombosis in Rats, Naunyn-Schmiedeberg' Arch. Pharmacol. 1977, vol. 301, pp. 115-119.
Pfeil et al., Synthese von Oxalactamen aus Aziridinium-tetrafluoroborat und Hydroxysäureestern, Agnew. Chem. 19
Lampe Thomas
Pernerstorfer Joseph
Perzborn Elisabeth
Pohlmann Jens
Röhrig Susanne
Anderson Rebecca
Bayer HealthCare AG
Connolly Bove & Lodge & Hutz LLP
Saeed Kamal A.
LandOfFree
Substituted oxazolidinones and their use in the field of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted oxazolidinones and their use in the field of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted oxazolidinones and their use in the field of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3749796